Effect of Dexmedetomidine for prevention of postoperative Nausea and Vomiting

Comparison of Dexmedetomidine, Dexamethasone and Metoclopramide for prevention of postoperative Nausea and Vomiting after Tympanomastoidectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016092629993N1

Enrollment

105

Registered

2017-03-23

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications of General Anesthesia.. Other specified complications of surgical and medical care, not elsewhere classified.

Interventions

Intervention 1: Intervention group 1: In group A (dexmed) 1 mcg / Kg Dexmedetomidine will be prescribed intravenously (IV), 10 minutes after tracheal intubation . Its volume will be increased to 4 ml

Prevention

Intervention group 1: In group A (dexmed) 1 mcg / Kg Dexmedetomidine will be prescribed intravenously (IV), 10 minutes after tracheal intubation . Its volume will be increased to 4 ml using Normal Sa

Intervention group 2: In group B (Dexa) 8 mg / IV Dexamethasone will be prescribed intravenously (IV), 10 minutes after tracheal. Its volume will be increased to 4 ml using Normal Saline.

Intervention group 3: In group C (Meto) 10 mg / IV Metoclopramide will be prescribed intravenously (IV), 10 minutes after tracheal. Its volume will be increased to 4 ml using Normal Saline.

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All adult patients at the age of 20-50 years; Patients with ASA class I -II; absence of drug abuse and Opioid addiction; Patients who fulfil Apfel criteria. Exclusion criteria: being allergic to drugs under study; Using of antiemetic drugs 48 hours before operation for any reason; BMI up to 35 kg / m2; pregnancy; not willing to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea and Vomiting. Timepoint: First 24 hours post Operation (every 6 houre). Method of measurement: Ask from the Patient based on the VAS score.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Before prescribing intervener Drugs (T0), At 5 minutes after prescribing (T1), At 30 minutes after prescribing (T2), At 5 minutes after Extubation (T3), At the time of enterance to recovery (T4). Method of measurement: By Sphygmomanometer, mmHg.;Pulse rate. Timepoint: Before prescribing intervener Drugs (T0), At 5 minutes after prescribing (T1), At 30 minutes after prescribing (T2), At 5 minutes after Extubation (T3), At the time of enterance to recovery (T4). Method of measurement: Counting in one minute.;O2 Saturation. Timepoint: Before Operation. Method of measurement: Pulse Oximetery.	—

Measure

Time frame

Blood pressure. Timepoint: Before prescribing intervener Drugs (T0), At 5 minutes after prescribing (T1), At 30 minutes after prescribing (T2), At 5 minutes after Extubation (T3), At the time of enterance to recovery (T4). Method of measurement: By Sphygmomanometer, mmHg.;Pulse rate. Timepoint: Before prescribing intervener Drugs (T0), At 5 minutes after prescribing (T1), At 30 minutes after prescribing (T2), At 5 minutes after Extubation (T3), At the time of enterance to recovery (T4). Method of measurement: Counting in one minute.;O2 Saturation. Timepoint: Before Operation. Method of measurement: Pulse Oximetery.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Hesamodin Modir

Arak University of Medical Sciences

he_modir@arakmu.ac.ir-

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026